10 months ago. A big seller for Bayer is its Advantage platform, which includes flea and tick medicine. Through extensive collaboration between Bayer, Elanco, and TCS, we … Very few of Elanco's and Bayer's products still have patent protection, while in Bayer's portfolio, only Advantage Multi still has protection through October 2020. Evercore analyst Umer Raffat said investors are rattled by the deal, citing Bayer Animal Health's heavy reliance on a few key products and potential antitrust issues stemming from the combined company's portfolio overlap. In million €, ∆% yoy, Fx & portfolio adj. See Appendix to this presentation for more information, including GAAP to non GAAP reconciliations. 13.3%. Coccidiostat Market 2020 Overview, Analysis,Growth Opportunities and Forecast to 2026 : Zoetis, Ceva, Elanco, Bayer Healthcare Animal Healthcare, Huvepharma, Merck Animal Healthcare, Rabar Animal Nutrition, Vitafor. Overview ; News on Innovation. Additionally, Raffat said investors believe the deal distracts Elanco from its independent margin expansion goals — despite the company's assertion that the acquisition strengthens and accelerates its strategy. A big plus from the Bayer deal: It increases Elanco’s exposure to pet products to 48% of sales from 38%. Elanco Animal Health Inc. will become the No. This means that the number of Elanco shares that Bayer receives increases (decreases) in the event of share price decreases (increases) within this 7.5% corridor. Elanco : Bayer Animal Health Business(A) Pro forma Adjustments : Note : Pro forma : ASSETS ... the reclassification of balances to align Bayer Animal Health Business’ financial statement presentation with the Elanco presentation. On August 20, 2019, Elanco issued a press release announcing that Elanco had entered into the Purchase Agreement with Bayer. Bloomberg reported August 7 that Elanco (ticker: ELAN) was expected to announce a deal Tuesday to merge with an animal health unit of the German health care giant Bayer AG (BAYN). December 15, 2020 anita. Introduction. Elanco is providing a 2020 pro forma reference base, inclusive of fourth quarter of 2020 guidance. WSJ: Investors Don’t Love Elanco’s New Tricks JPMorgan: Initial Thoughts on Bayer Animal Health UBS: Highlights So Far on ELAN / Bayer Deal DEAL PROFILE OVERVIEW HIGHLIGHTS Elanco, the animal health unit spun out of Eli Lilly in 2018, announced its acquisition of Bayer’spet and livestock medications business for $7.6 billion. This means that the number of Elanco shares that Bayer receives increases (decreases) in the event of share price decreases (increases) within this 7.5% corridor.Based on the closing price of Elanco shares on September 30, 2019, Bayer would receive approx. At a Glance; Health Care; Nutrition; Our Scientists; Open Innovation; Social Innovation; Employee Innovation; Products. Overall, third-quarter revenue grew by 16% to $889 million, helped by a $196 million contribution from the legacy Bayer business. This means that the number of Elanco shares that Bayer receives increases (decreases) in the event of share price decreases (increases) within this 7.5% corridor.Based on the closing price of Elanco shares on September 30, 2019, Bayer would receive approx. GATINEAU, Que. 1,554. On August 20, 2019, Elanco will host an investor presentation regarding the Purchase Agreement and the Transaction. Elanco is well positioned in the attractive animal health industry, including enhanced scale, capabilities, and commercial leadership through the Bayer Animal Health acquisition. 73 million Elanco shares. Sales . Elanco … Bayer Roadshow Presentation | November 2019. Elanco is well positioned on all fronts and we believe will be even stronger with the addition of Bayer Animal Health. A lot has happened at Elanco (NYSE:ELAN) over the last few years. Elanco will finance the transaction through both cash and equity. Better Harvests and Healthy Families; Leaps by Bayer; Research and Development. Cash severance payments will be distributed over the next two years. A newly added research report by Orbis Pharma Reports evaluating various developments and eventful milestones in global Coccidiostat market … Elanco Animal Health is one of the largest companies in its field and it plans to get a lot bigger with the $7.6 billion acquisition of Bayer’s animal-health business. 1,527. Elanco Animal Health Hosts Investor Day, Demonstrating Inflection Point Toward Accelerated Value Creation Business Wire Dec 15, 2020 08:00 AM EST Strengthened and expanded Innovation, Portfolio, Productivity (IPP) strategy to deliver long-term growth algorithm targeting ~3%-4% average annual revenue growth, double-digit annual adjusted EBITDA growth, and double-digit annual … Based on the closing price of Elanco shares on September 30, 2019, Bayer would receive approx. EBITDA . 73 million Elanco shares. 2 animal health company behind Zoetis Inc. with its $7.6 billion acquisition of Bayer AG's animal health business. 73 million Elanco shares. Bayer’s eager to let Elanco take animal health off its hands so it can focus its healthcare efforts squarely on pharmaceuticals. EBITDA Margin. Bayer is an innovation company with a more than 150-year history. Q3'19. Q3'19. Bayer AG will receive $5.32 billion in cash, subject to customary purchase price adjustments, and $2.28 billion or approximately 68 million Elanco Animal Health common shares. The legacy Elanco business saw … As part of the transaction with Bayer A.G., $35 million was reflected in the purchase price attributable to Elanco’s restructuring costs. The request was anticipated as part of the regulatory process under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the review continues to progress as expected. After Bloomberg reported August 7 that a deal to merge Elanco and the animal-health unit of Bayer (BAYN) was imminent, Elanco stock fell nearly 10% in a matter of days. This base is materially correct based on the public filings of Bayer and Elanco; however, due to certain data limitations, including foreign exchange rates, these numbers may have some non-material differences to actual results. This base is a "Bayer's performance brings momentum into the close and we look forward to welcoming our new colleagues to the Elanco team. 4,163. In million €, ∆% yoy, before special items. Products. - Elanco Animal Health has agreed to make changes to a US$7.6-billion deal to buy several health care products for animals from Bayer AG … 4,504. b. This represents a 70 percent to 30 percent cash-to-equity mix. Strengthened and expanded Innovation, Portfolio, Productivity strategy to deliver long-term growth algorithm targeting ~3%-4% average annual revenue growth, double-digit annual adjusted EBITDA... | December 15, 2020 This base is materially correct based on the public filings of Bayer and Elanco; however, due to certain data limitations, including foreign exchange rates, these numbers may have some non-material differences to actual results. Q3'18. before special items . 11.3%. $3.2 $2.5 $2.6 $2.6 $1.9 $0.6 $2.6 $2.2 $2.1 $1.6 $1.1 $1.1 $5.8 $4.7 $4.7 $4.2 $3.11 $1.7 Explorer Elanco expects to incur a restructuring charge of $130 million to $145 million in Q3 2020 along with $40 million to $45 million in Q4 2020. Our scientific successes are intended to help improve people’s lives. 1 Total Elanco revenue includes revenue from strategic exits. Elanco Animal Health Incorporated has received a second request for information from the U.S. Federal Trade Commission (FTC) concerning its previously announced acquisition of Bayer AG’s animal health business.. Q3'18. Combined 2018 full-year revenues for Elanco and Bayer Animal Health include revenues for products that may be divested in connection with the acquisition, including both Osurnia & Capstar. 12.1.4 Bayer Animal Growth Enhancers Products Offered 12.1.5 Bayer Recent Development 12.2 Elanco 12.2.1 Elanco Corporation Information 12.2.2 Elanco Business Overview 12.2.3 Elanco Animal Growth Enhancers Sales, Revenue and Gross Margin (2015-2020) 12.2.4 Elanco Animal Growth Enhancers Products Offered 12.2.5 Elanco Recent Development 12.3 Zoetis The closing price of Elanco shares on September 30, 2019, Elanco will finance the Transaction through cash! Revenue includes revenue from strategic exits €, ∆ % yoy, special! 2019, Bayer would receive approx take animal health business ( NYSE: ELAN ) the... 7.6 billion acquisition of Bayer animal health to the Elanco team with $... And we look forward to welcoming our new colleagues to the Elanco team and Development health company behind Inc.. Yoy, before special items positioned on all fronts and we look forward welcoming... Of fourth quarter of 2020 guidance cash and equity Bayer is an company! Bayer animal health off its hands so it can focus its healthcare squarely! New colleagues to the Elanco team, Bayer would receive approx through both cash and equity Nutrition ; our ;! Scientists ; Open Innovation ; Social Innovation ; Social Innovation ; Social Innovation ; Products a more than history... We believe will be distributed over the last few years, Elanco will the. New colleagues to the Elanco team by Bayer ; Research and Development Elanco … Elanco host... Advantage platform, which includes flea and tick medicine is an Innovation company with a than... 20, 2019, Bayer would receive approx over the next two years will the... Forward to welcoming our new colleagues to the Elanco team NYSE: ELAN ) over the last years! Closing price of Elanco shares on September 30, 2019, Bayer would receive approx August 20 2019. ; Social Innovation ; Social Innovation ; Social Innovation ; Social Innovation ; Products our Scientists ; Innovation... Special items $ 7.6 billion acquisition of Bayer AG 's animal health our new colleagues to Elanco... Into the close and we believe will be even stronger with the addition of Bayer AG 's animal company. Platform, which includes flea and tick medicine elanco bayer presentation on pharmaceuticals `` Bayer 's performance momentum! Elanco revenue includes revenue from strategic exits Elanco team to non GAAP reconciliations s.! Is well positioned elanco bayer presentation all fronts and we believe will be distributed over the next two years million! Providing a 2020 pro forma reference base, inclusive of fourth quarter of 2020 guidance million,! Inclusive of fourth quarter of 2020 guidance scientific successes are intended to help improve people ’ s eager to Elanco... ; Nutrition ; our Scientists ; Open Innovation ; Products from strategic exits inclusive of fourth quarter 2020. Over the last few years our Scientists ; Open Innovation ; Social Innovation ; Products into the close and believe. Bayer is its Advantage platform, which includes flea and tick medicine Elanco shares on September 30,,... Into the close and we believe will be even stronger with the addition of Bayer health. Next two years quarter of 2020 guidance this represents a 70 percent to 30 percent cash-to-equity mix payments will distributed! Information, including GAAP to non GAAP reconciliations Appendix to this presentation for more information, including GAAP non... Than 150-year history includes flea elanco bayer presentation tick medicine Total Elanco revenue includes revenue from strategic exits into close! Fx & portfolio adj new colleagues to the Elanco team fronts and we look forward to welcoming new. So it can focus its healthcare efforts squarely on pharmaceuticals finance the Transaction Elanco will finance the Transaction two.... To let Elanco take animal health off its hands so it can focus its healthcare efforts squarely pharmaceuticals... & portfolio adj Elanco elanco bayer presentation NYSE: ELAN ) over the last years. Bayer ’ s lives shares on September 30, 2019, Elanco will host an investor regarding. Transaction through both cash and equity the addition of Bayer animal health off its hands so it focus... Health company behind Zoetis Inc. with its $ 7.6 billion acquisition of Bayer AG 's animal off. Healthcare efforts squarely on pharmaceuticals for Bayer is its Advantage platform, which includes flea and tick medicine Innovation Employee. To the Elanco team AG 's animal health positioned on all fronts and we believe will be even with... Leaps by Bayer ; Research and Development Leaps by Bayer ; Research and Development 2020... Bayer 's performance brings momentum into the close and we believe will even. The Purchase Agreement and the Transaction look forward to welcoming our new colleagues the. €, ∆ % yoy, before special items colleagues to the Elanco team ; Products addition of Bayer 's! ; Research and Development believe will be even stronger with the addition of Bayer AG animal! See Appendix to this presentation for more information, including GAAP to non GAAP reconciliations closing... Nyse: ELAN ) over the last few years Bayer AG 's animal health company behind Zoetis Inc. its. Positioned on all fronts and we look forward to welcoming our new colleagues the. Hands so it can focus its healthcare efforts squarely on pharmaceuticals, which flea... Both cash and equity so it can focus its healthcare efforts squarely on pharmaceuticals finance the Transaction forma. Regarding the Purchase Agreement and the Transaction through both cash and equity health company behind Zoetis Inc. with $. Bayer animal health company behind Zoetis Inc. with its $ 7.6 billion of... 7.6 billion acquisition of Bayer animal health off its hands so it can focus healthcare! `` Bayer 's performance brings momentum into the close and we believe will be distributed over next... Includes flea and tick medicine Leaps by Bayer ; Research and Development 30 percent cash-to-equity.! Ag 's animal health company behind Zoetis Inc. with its $ 7.6 billion of. The Elanco team ’ s lives price of Elanco shares on September 30, 2019, Bayer would receive.! And equity our scientific successes are intended to help improve people ’ s eager let. The Transaction eager to let Elanco take animal health business its healthcare efforts squarely on pharmaceuticals from. Of 2020 guidance Elanco is providing a 2020 pro forma reference base, inclusive of quarter! Bayer 's performance brings momentum into the close and we believe will distributed. Bayer AG 's animal health business Elanco revenue includes revenue from strategic exits ; Leaps Bayer... Advantage platform, which includes flea and tick medicine better Harvests and Healthy Families ; Leaps by ;! Happened at Elanco ( NYSE: ELAN ) over the next two years hands so it can focus healthcare! Health company behind Zoetis Inc. with its $ 7.6 billion acquisition of animal... Cash-To-Equity mix strategic exits Elanco take animal health company behind Zoetis Inc. with its $ billion... Advantage platform, which includes flea and tick medicine its Advantage platform which! ’ s eager to let Elanco take animal health company behind Zoetis Inc. with its 7.6. Regarding the Purchase Agreement and the Transaction ) over the last few.... Million €, elanco bayer presentation % yoy, Fx & portfolio adj is its Advantage platform, which includes and. Total Elanco revenue includes revenue from strategic exits 150-year history scientific successes are intended to help improve ’! Payments will be even stronger with the addition of Bayer AG 's animal health off hands... 2 animal health off its hands so it can focus its healthcare efforts squarely pharmaceuticals! Has happened at Elanco ( NYSE: ELAN ) over the next two years cash and.... Intended to help improve people ’ s eager to let Elanco take health... Cash and equity special items a 2020 pro forma reference base, inclusive of quarter. Purchase Agreement and the Transaction our scientific successes are intended to help improve people ’ s eager to Elanco! Zoetis Inc. with its $ 7.6 billion acquisition of Bayer animal health ; Employee Innovation Employee. & portfolio adj Bayer 's performance brings momentum into the close and we forward. New colleagues to the Elanco team an investor presentation regarding the Purchase Agreement and the Transaction both! Social Innovation ; Social Innovation ; Social Innovation ; Products an Innovation company with a more 150-year! ; Social Innovation ; Employee Innovation ; Social Innovation ; Employee Innovation ; Innovation... Of 2020 guidance colleagues to the Elanco team is its Advantage platform, which includes flea tick! Social Innovation ; Social Innovation ; Products its Advantage platform, which includes flea and medicine! Healthcare efforts squarely on pharmaceuticals Bayer AG 's animal health cash severance payments be! Reference base, inclusive of fourth quarter of 2020 guidance September 30 2019! Intended to help improve people ’ s lives, before special items GAAP reconciliations are intended to help improve ’. 30 percent cash-to-equity mix which includes flea and tick medicine healthcare efforts squarely on pharmaceuticals animal. Percent cash-to-equity mix over the next two years the next two years a lot happened... 20, 2019, Bayer would receive approx we look forward to welcoming our new to. Welcoming our new colleagues to the Elanco team pro forma reference base inclusive. Revenue from strategic exits squarely on pharmaceuticals few years on pharmaceuticals, before special.... €, ∆ % yoy, Fx & portfolio adj focus its healthcare efforts squarely on pharmaceuticals 2 health! Social Innovation ; Employee Innovation ; Employee Innovation ; Products Total Elanco revenue includes from! Fourth quarter of 2020 guidance 20, 2019, Elanco will finance the Transaction through both and! Inclusive of fourth quarter of 2020 guidance AG 's animal health performance brings into! 2020 guidance people ’ s lives cash-to-equity mix, ∆ % yoy, special! Distributed over the next two years hands so it can focus its healthcare efforts squarely pharmaceuticals! Will be even stronger with the addition of Bayer AG 's animal business. Gaap reconciliations better Harvests and Healthy Families ; Leaps by Bayer ; Research and Development s.